Enoxaparin Therapeutic Dosing
For therapeutic anticoagulation in adults, enoxaparin is dosed at 1 mg/kg subcutaneously every 12 hours for patients under 75 years with normal renal function (CrCl >30 mL/min), with critical dose reductions required for elderly patients and those with renal impairment.
Standard Weight-Based Dosing
Acute Coronary Syndromes (STEMI/NSTEMI)
Patients <75 years:
- 30 mg IV bolus followed immediately by 1 mg/kg SC every 12 hours 1
- First subcutaneous dose given shortly after the IV bolus
Patients ≥75 years:
- 0.75 mg/kg SC every 12 hours without IV bolus 1
- This represents a 25% dose reduction to mitigate bleeding risk in elderly patients
Venous Thromboembolism Treatment
Standard therapeutic dosing:
The twice-daily regimen is preferred over once-daily dosing based on post-hoc data suggesting superior efficacy 4, though once-daily dosing remains an acceptable alternative for VTE treatment in adults.
Renal Impairment Adjustments
This is where most dosing errors occur—renal function is the single most critical factor requiring dose modification.
Severe Renal Impairment (CrCl <30 mL/min)
- 1 mg/kg SC once daily (50% frequency reduction) 1
- This applies to all therapeutic indications
- Alternative: Consider switching to unfractionated heparin 1
The evidence is clear: enoxaparin clearance decreases by 44% in severe renal impairment, leading to significant drug accumulation with standard dosing 5, 6. Research demonstrates that without dose adjustment, patients with CrCl <30 mL/min have 3-fold increased odds of supratherapeutic anti-Xa levels 7.
Moderate Renal Impairment (CrCl 30-50 mL/min)
While guidelines don't mandate dose reduction for CrCl 30-50 mL/min 1, research evidence suggests caution:
- Enoxaparin clearance decreases by 31% in moderate renal impairment 5
- Consider dose reduction to 0.8 mg/kg every 12 hours after the first full dose 5, 6
- Twice-daily regimens carry higher risk of supratherapeutic levels in this population 7
Critical pitfall: The 2015 AHA guidelines only address CrCl <30 mL/min 1, but pharmacokinetic data clearly shows accumulation begins at CrCl <50 mL/min 5, 6. Clinical judgment favors dose adjustment in the 30-50 mL/min range, particularly for twice-daily dosing.
Special Populations
Obesity
No dose adjustment required for obese patients 7, 8
- Standard weight-based dosing (1 mg/kg) is appropriate
- Anti-Xa levels increase only minimally with BMI (0.01 IU/mL per kg/m²), insufficient to cause supratherapeutic levels 7
Extreme Low Body Weight (<40 kg)
- Consider 0.5 mg/kg SC daily for prophylactic-intensity anticoagulation 8
- For therapeutic dosing in extremely underweight patients, weight-based dosing with anti-Xa monitoring may be warranted
- This is an evidence gap; pediatric dosing strategies may need adaptation
Advanced Age (≥80 years)
Recent data suggests age is more critical than mild-to-moderate renal impairment for achieving target anti-Xa levels 9:
- Patients ≥80 years require lower doses than younger patients to achieve therapeutic levels
- Consider empiric dose reduction even with preserved renal function
- Female sex also independently increases risk of supratherapeutic levels 10
Anti-Xa Monitoring
The ASH 2018 guidelines suggest against routine anti-Xa monitoring for dose adjustment in renal impairment 11, citing:
- Poor test standardization between laboratories
- Weak correlation between anti-Xa levels and bleeding events
- Lack of evidence that monitoring improves outcomes
However, if monitoring is performed:
- Trough levels are preferred over peak levels 12
- Target trough: <0.4 IU/mL for once-daily dosing, <0.5 IU/mL for twice-daily dosing 12
- Peak levels (4 hours post-dose) are poorly predictive of clinical outcomes
Critical Safety Considerations
Do Not Switch Between Anticoagulants
Never switch between enoxaparin and unfractionated heparin during acute treatment—this significantly increases bleeding risk 1. If switching is absolutely necessary due to renal failure, allow appropriate washout periods.
Concomitant Medications
Avoid combining enoxaparin with:
- NSAIDs (including COX-2 inhibitors) 13
- Antiplatelet agents unless clear indication (mechanical valves, ACS, recent stents) 13
- Certain antibiotics that potentiate anticoagulation 13
Risk Factors for Supratherapeutic Levels
Beyond renal impairment, monitor closely in patients with 10:
- Female sex
- Lower BMI
- Concomitant corticosteroid use
- Multiple doses administered (accumulation risk)
Duration and Discontinuation
For VTE treatment, continue therapeutic anticoagulation for at least 3-6 months depending on clinical circumstances 2, 4. When discontinuing, abrupt cessation is preferred over gradual tapering 13.